Our findings demonstrate that bevacizumab-mediated autophagy was decreased in IRF1 down-regulation tumors, which was coincident with increased apoptosis, and an improvement in efficacy of anti-VEGF therapy in glioma xenografts. The gene discussed is IRF1; the disease is glioma.